公开(公告)号：USPP35199P3

公开(公告)日：2023-05-30

申请号：US17958467

申请日：2022-10-03

申请人： LAZZERI GENETICA S.A.S. di DALLAGO FRANCO & C.

发明人： Johannes Nebelmeir

IPC分类号： A01H5/02 ,  A01H6/38

CPC分类号： A01H6/385

摘要： A new and distinct cultivar of Poinsettia plant named ‘LAZZPO1531’, characterized by its upright “V”-shaped and uniformly mounding plant habit; moderately vigorous to vigorous growth habit; freely branching habit and strong stems; dark green-colored leaves; full inflorescences with medium to large deep red-colored flower bracts; and excellent post-production longevity.

公开(公告)号：US20220241241A1

公开(公告)日：2022-08-04

申请号：US17611777

申请日：2020-05-25

申请人： ISTITUTO NAZIONALE DI GENETICA MOLECOLARE - INGM ,  OSPEDALE SAN RAFFAELE S.R.L. ,  IRBM S.P.A.

发明人： Raffaele DE FRANCESCO ,  Lorena DONNICI ,  Luca GUIDOTTI ,  Matteo IANNACONE ,  Romano DI FABIO ,  Vincenzo SUMMA ,  Adolfo PRANDI ,  Pietro RANDAZZO ,  Leda IVANOVA BENCHEVA ,  Marilenia DE MATTEO ,  Luca FERRANTE ,  Davide GORNATI ,  Alessandro GRILLO

IPC分类号： A61K31/407 ,  C07D515/14 ,  C07D513/14 ,  A61P31/20 ,  A61K39/395 ,  A61K38/21 ,  A61K31/522 ,  A61K31/513 ,  A61K31/7072 ,  A61K31/675 ,  A61K31/437 ,  A61K31/7084 ,  A61K31/506 ,  A61K31/445 ,  A61K39/29

摘要： The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.

公开(公告)号：US10213379B2

公开(公告)日：2019-02-26

申请号：US10540296

申请日：2003-12-22

申请人： Maria Acelia Marrero Miragaya ,  Ana Aguilera Barreto ,  Lisette Gonzalez Chavez ,  Eduardo Martinez Diaz ,  Beatriz Torrez Cabrera ,  Karelia Cosme Diaz ,  Luciano Francisco Hernandez Marrero ,  Beatriz Tamargo Santos

发明人： Maria Acelia Marrero Miragaya ,  Ana Aguilera Barreto ,  Lisette Gonzalez Chavez ,  Eduardo Martinez Diaz ,  Beatriz Torrez Cabrera ,  Karelia Cosme Diaz ,  Milesa Yeni Sarmiento Mayea ,  Luciano Francisco Hernandez Marrero ,  Beatriz Tamargo Santos

IPC分类号： A61K9/02 ,  A61K9/00 ,  A61K38/16

摘要： Pharmaceutical formulations in suppository form, containing thrombolytic agents, which are able to penetrate rectal mucous, for the treatment of acute hemorrhoid diseases and/or diseases of thrombotic origin.

公开(公告)号：US09603900B2

公开(公告)日：2017-03-28

申请号：US14839114

申请日：2015-08-28

申请人： Centro de Ingenieria Genetica y Biotecnologia

发明人： Mario Pablo Estrada Garcia ,  Juana Maria Lugo Gonzalez ,  Yamila Carpio Gonzalez ,  Carolina Tafalla Pineiro

IPC分类号： A61K9/08 ,  A61K38/22 ,  A61K31/7056 ,  A61K9/00 ,  A61K9/51

CPC分类号： A61K38/2278 ,  A61K9/0019 ,  A61K9/0056 ,  A61K9/08 ,  A61K9/5153 ,  A61K31/7056 ,  A61K38/22 ,  A61K2300/00

摘要： The present invention relates to the use of pituitary adenylate cyclase activating polypeptide (PACAP) in the treatment of viral diseases and infectious diseases caused by viruses in aquatic organisms. PACAP, alone or combined with an antiviral molecule, demonstrated its effectiveness by increasing the survival of fish or crustaceans infected by viruses when it was administered orally, by injection or by immersion baths. Furthermore, it was observed that treated organisms keep or increase its weight as compared to infected and non-treated organisms. PACAP or PACAP-containing combinations decreased the viral load in tissues and organs susceptible to viral infections as it was determined by RT-PCR.

公开(公告)号：US09549977B2

公开(公告)日：2017-01-24

申请号：US14238377

申请日：2012-08-24

申请人： Juana Maria Lugo Gonzalez ,  Yamila Carpio Gonzalez ,  Mario Pablo Estrada Garcia

发明人： Juana Maria Lugo Gonzalez ,  Yamila Carpio Gonzalez ,  Mario Pablo Estrada Garcia

IPC分类号： A61K39/39 ,  A61K39/002 ,  A61K39/12 ,  A61K39/205 ,  A61K39/00 ,  A61K39/02

CPC分类号： A61K39/39 ,  A61K39/0003 ,  A61K39/002 ,  A61K39/0208 ,  A61K39/12 ,  A61K39/205 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/55516 ,  A61K2039/55566 ,  A61K2039/6031 ,  C12N2720/10034 ,  C12N2760/20034 ,  C12N2770/24334

摘要： The present invention relates to the use of the pituitary adenylate cyclase activating peptide (PACAP) as a molecular adjuvant for vaccines. Among other applications, these vaccines may be used in the protection against infectious agents such as viruses, bacteria and ectoparasites affecting mammals, birds and aquatic organisms. The PACAP, combined with a particular antigen, demonstrates its effectiveness as adjuvant increasing the host immune response against that antigen. This type of response can be observed when the vaccine compositions or combinations that include PACAP are administered orally, by injection, or by immersion baths, in case of aquatic organisms.

摘要翻译： 本发明涉及垂体腺苷酸环化酶活化肽（PACAP）作为疫苗的分子佐剂的用途。 除其他应用之外，这些疫苗可用于防止感染性物质的侵害，例如影响哺乳动物，鸟类和水生生物的病毒，细菌和外寄生虫。 与特定抗原结合的PACAP证明其作为佐剂增加针对该抗原的宿主免疫应答的有效性。 当在水生生物的情况下，当疫苗组合物或包含PACAP的组合在口服，注射或浸泡浴中进行给药时，可以观察到这种反应。

公开(公告)号：US09375459B2

公开(公告)日：2016-06-28

申请号：US14005855

申请日：2012-03-21

申请人： María del Carmen Abrahantes Pérez ,  Glay Chinea Santiago ,  Eduardo Martínez Diaz ,  Hilda Elisa Garay Pérez ,  Osvaldo Reyes Acosta ,  Ernesto Lopez Mola ,  Cruz Matilde Lopez Abad ,  Sonia Gonzalez Blanco

发明人： María del Carmen Abrahantes Pérez ,  Glay Chinea Santiago ,  Eduardo Martínez Diaz ,  Hilda Elisa Garay Pérez ,  Osvaldo Reyes Acosta ,  Ernesto Lopez Mola ,  Cruz Matilde Lopez Abad ,  Sonia Gonzalez Blanco

IPC分类号： A61K38/12 ,  A61K31/4025 ,  A61K45/06 ,  C07K7/64 ,  C07K7/06 ,  C07K7/08 ,  A61K47/48 ,  A61K38/00 ,  A61K9/00 ,  A61K9/127 ,  A61K9/50

CPC分类号： A61K38/12 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/5031 ,  A61K31/4025 ,  A61K38/00 ,  A61K45/06 ,  A61K47/60 ,  C07K7/06 ,  C07K7/08 ,  C07K7/64

摘要： The present invention comprises cyclic peptides bearing antitumor and antiangiogenic properties, as well as their corresponding pharmaceutically-suitable salts and also pharmaceutical compositions containing it. These cyclic peptides are used to prepare medicines for human and/or veterinary therapeutics, and additionally in diagnosis. These compounds can be used to detect, monitor and/or control a range of cellular proliferation-related disorders, such as oncological diseases and undesired angiogenesis. Moreover, they can be included as part of controlled release systems, and used more precisely in the field of nanobiotechnology, either because of their self-assembly capacity or as part of other systems.

摘要翻译： 本发明包括具有抗肿瘤和抗血管生成特性的环肽，以及它们相应的药学上合适的盐以及含有它的药物组合物。 这些环肽用于制备用于人和/或兽医治疗剂的药物，另外用于诊断。 这些化合物可用于检测，监测和/或控制一系列细胞增殖相关疾病，例如肿瘤疾病和不期望的血管生成。 此外，它们可以作为控制释放系统的一部分进行纳入，并且在纳米生物技术领域更加精确地使用，无论是由于其自组装能力还是作为其他系统的一部分。

公开(公告)号：US09278118B2

公开(公告)日：2016-03-08

申请号：US14518242

申请日：2014-10-20

申请人： Centro de Ingenieria Genetica Y Biotecnologia ,  BIOREC S.A.

发明人： Silvio Ernesto Perea Rodriguez ,  Yasser Perera Negrin ,  Arielis Rodríguez Ulloa ,  Jeovanis Gil Valdés ,  Yassel Ramos Gómez ,  Lila Rosa Castellanos Serra ,  Lázaro Hiram Betancourt Núñez ,  Aniel Sánchez Puente ,  Jorge Fernández de Cossio Dorta Duque ,  Boris Ernesto Acevedo Castro ,  Luis Javier González López ,  Vladimir Besada Pérez ,  Daniel Fernando Alonso ,  Daniel Eduardo Gomez

IPC分类号： A61K38/04 ,  C07K7/04 ,  A61K38/08 ,  A61K31/7048 ,  A61K31/282 ,  A61K31/7068 ,  A61K31/7076 ,  A61K31/136

CPC分类号： A61K38/08 ,  A61K31/136 ,  A61K31/282 ,  A61K31/337 ,  A61K31/407 ,  A61K31/475 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/555 ,  A61K31/675 ,  A61K31/69 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K31/7076 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

摘要： This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa, velcade (bortezomib), cytarabine (Ara C), fludarabine and mitroxantrone. The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

摘要翻译： 本发明涉及含有酪蛋白激酶2（CK2）肽抑制剂（称为P15）以及癌症治疗中使用的标准化学治疗药物并且分开或依次给药的药物组合。 化疗药物包括顺铂，紫杉醇，长春花生物碱，5-氟尿嘧啶，多柔比星，环磷酰胺，依托泊苷，丝裂霉素C，伊马替尼，iressa，velcade（硼替佐米），阿糖胞苷（Ara C），氟达拉滨和米托蒽醌。 P15肽与抗癌药物之间的协同作用实现了组合中每种细胞抑制药物的有效浓缩，其比单独的每种细胞抑制药物低10至100倍。 本发明中描述的药物组合物与抗癌治疗剂报道的药物组合物相比表现出较低的毒性，因此它代表其用于癌症治疗的关键优势。 此外，通过用P15肽进行预处理，该药物组合的连续施用导致难治性肿瘤对抗癌治疗剂的化学敏感性。

公开(公告)号：US09226946B2

公开(公告)日：2016-01-05

申请号：US14490856

申请日：2014-09-19

申请人： Centro de Ingenieria Genetica Y Biotecnologia

发明人： Silvio Ernesto Perea Rodríguez ,  Yasser Perera Negrín ,  Arielis Rodríguez Ulloa ,  Jeovanis Gil Valdés ,  Yassel Ramos Gómez ,  Lila Rosa Castellanos Serra ,  Lázaro Hiram Betancourt Núñez ,  Aniel Sánchez Puente ,  Jorge Fernández de Cossio Dorta Duque ,  Boris Ernesto Acevedo Castro ,  Luis Javier González López ,  Vladimir Besada Pérez ,  Daniel Fernando Alonso ,  Daniel Eduardo Gomez

IPC分类号： A61K38/04 ,  C07K7/00 ,  A61K38/08 ,  A61K31/555 ,  A61K33/24 ,  A61K45/06 ,  A61K31/337 ,  A61K31/407 ,  A61K31/475 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/675 ,  A61K31/69 ,  A61K31/704

CPC分类号： A61K38/08 ,  A61K31/136 ,  A61K31/282 ,  A61K31/337 ,  A61K31/407 ,  A61K31/475 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/555 ,  A61K31/675 ,  A61K31/69 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K31/7076 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

摘要： This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

摘要翻译： 本发明涉及含有酪蛋白激酶2（CK2）肽抑制剂（称为P15）以及癌症治疗中使用的标准化学治疗药物并且分开或依次给药的药物组合。 化疗药物包括顺铂，紫杉醇，长春花生物碱，5-氟尿嘧啶，多柔比星，环磷酰胺，依托泊苷，丝裂霉素C，伊马替尼，iressa和velcade（硼替佐米）。 P15肽与抗癌药物之间的协同作用实现了组合中每种细胞抑制药物的有效浓缩，其比单独的每种细胞抑制药物低10至100倍。 本发明中描述的药物组合物与抗癌治疗剂报道的药物组合物相比表现出较低的毒性，因此它代表其用于癌症治疗的关键优势。 此外，通过用P15肽进行预处理，该药物组合的连续施用导致难治性肿瘤对抗癌治疗剂的化学敏感性。

公开(公告)号：US09034339B2

公开(公告)日：2015-05-19

申请号：US13859314

申请日：2013-04-09

申请人： Centro De Ingenieria Genetica Y Biotecnologia

发明人： Yamila Carpio Gonzalez ,  Mario Pablo Estrada Garcia

IPC分类号： A61K39/395 ,  A61K39/00 ,  A61K39/38 ,  C07K1/00 ,  C07K14/00 ,  C07K17/00 ,  C07H21/02 ,  C07K14/435 ,  A61K38/00

CPC分类号： A61K39/0003 ,  A23K50/80 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/552 ,  C07K14/43509 ,  C07K2319/00

摘要： The present invention is related with the isolation and cloning of a new gene, the production of the protein encoded by this gene by using recombinant systems, and the use of this antigen in a vaccine formulation as a purified protein and/or naked DNA, to induce an immune response in aquatic organisms against different ectoparasite species, including the known as sea lice, and pathogens associated with these infestations. The vaccine preparations, administered by oral route, immersion bath or injection, demonstrated its efficacy by producing IgM humoral immune response and reducing the number of parasites per fish in the vaccinated fishes.

摘要翻译： 本发明涉及新基因的分离和克隆，通过使用重组系统产生由该基因编码的蛋白质，以及将该抗原在疫苗制剂中用作纯化的蛋白质和/或裸DNA， 在水生生物中诱导针对不同外寄生物种的免疫应答，包括已知的海虱和与这些侵染有关的病原体。 通过口服途径，浸浴或注射给药的疫苗制剂通过产生IgM体液免疫应答并减少接种的鱼类中每条鱼的寄生虫数量来证明其功效。

公开(公告)号：US08833306B2

公开(公告)日：2014-09-16

申请号：US12094339

申请日：2006-11-20

申请人： Juana Maria Lugo González ,  Mario Pablo Estrada Garcia ,  Alina Rodriguez Mallon ,  Yamila Carpio González ,  Antonio Morales Rojas ,  Osmany Rodrigo González De Sosa ,  Reynold Morales Fernández ,  Fidel Francisco Herrera Miyares

发明人： Juana Maria Lugo González ,  Mario Pablo Estrada Garcia ,  Alina Rodriguez Mallon ,  Yamila Carpio González ,  Antonio Morales Rojas ,  Osmany Rodrigo González De Sosa ,  Reynold Morales Fernández ,  Fidel Francisco Herrera Miyares

IPC分类号： A61K38/18 ,  A01K61/00 ,  A01K61/02

CPC分类号： A61K38/17 ,  A01K61/80 ,  A23K20/147 ,  A23K50/80 ,  C07K14/57563 ,  Y02A40/845

摘要： The present invention is related to the use of variants of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) to stimulate the growth and to improve the immunological system of aquatic organisms. The variants of the peptide were provided by immersion, injection or as a food additive.

摘要翻译： 本发明涉及使用垂体腺苷酸环化酶活化多肽（PACAP）的变体来刺激生长并改善水生生物的免疫系统。 通过浸渍，注射或作为食品添加剂提供肽的变体。